Condition (MeSH)
Retinal Neovascularization
ClinicalTrials.gov lists 24 trials for Retinal Neovascularization or a narrower condition beneath it. Notal Vision Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
24 of the 24 trials are tagged with Retinal Neovascularization itself; the rest are tagged with a narrower condition beneath it.
When did Retinal Neovascularization trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2013 | 3 |
| 2012 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 24 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Retinal Neovascularization trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Not applicable | 3 |
| Observational | 5 |
How many Retinal Neovascularization trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 16 |
| Terminated | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Retinal Neovascularization trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Notal Vision Inc. | 2 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
| Genzyme, a Sanofi Company | 1 |
| National Eye Institute (NEI) | 1 |
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Retinal Neovascularization? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Brolucizumab | 1 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ranibizumab PRN | 2 |
| Bevacizumab 1 | 2 |
| Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) | 1 |
| rAAV.sFlt-1 | 1 |
| 2.0 aflibercept | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Retinal Neovascularization trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Vitreous haemorrhage - Fellow eye | 46 | 1 |
| Vitreous haemorrhage - Study eye | 46 | 1 |
| Cerebral infarction | 12 | 1 |
| Hypertension | 12 | 1 |
| Cataract - Study eye | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Retinal Neovascularization? (120)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| RATE OF AND TIME TO COMPLETE RETINAL VASCULARIZATION IN PREMATURE INFANTS AND ASSOCIATED FACTORS. | Retina (Philadelphia, Pa.) | 2023 | Yes |
| LONG-TERM CHANGES IN CHOROIDAL THICKNESS IN EYES WITH TYPE 3 MACULAR NEOVASCULARIZATION. | Retina (Philadelphia, Pa.) | 2021 | Yes |
| Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. | Current opinion in ophthalmology | 2021 | Yes |
| Optical Coherence Tomography Angiography of Macular Perfusion Changes after Anti-VEGF Therapy for Diabetic Macular Edema: A Systematic Review. | Journal of diabetes research | 2021 | Yes |
| Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. | JAMA ophthalmology | 2020 | Yes |
Showing 5 of 120 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.